Semaglutide
The active ingredient in Ozempic and Wegovy. Activates a single GLP-1 pathway that slows gastric emptying, reduces appetite, and improves insulin sensitivity. A clinically established option with extensive data and a strong track record across a range of patients.
- Mechanism
- Single GLP-1 pathway
- Average loss
- ~15% body weight (68-week data)
- Best for
- Tolerability, established protocols